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https://www.verywell.com/rheumatoid-arthritis-explained-with-pictures-190351 
Definition  
Rheumatoid arthritis (RA) is the most common long-
lasting autoimmune inflammatory disorder that primarily 
affects joints typically involved on both sides of the body with 
erosions of the cartilage and bone sometimes causes joint 
deformity, but can also affect other organs with significant 
negative impact on the ability to perform daily activities, 
including work and household tasks, and health related quality 
of life, and it increases mortality. 
 
rheumatology.org/Portals/0/Files/ACR%202015%20RA%20Guideline.pdf cdc.gov/arthritis/basics/rheumatoid.htm 
Epidemiology   
http://emedicine.medscape.com/article/331715-overview#a5 https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Epidemiology 
• Worldwide, the annual incidence of RA is approximately 3 
cases per 10,000 population, and the prevalence rate is 
approximately 1%, increasing with age and peaking between 
the ages of 35 and 50 years.   
• RA is uncommon under the age of 15 and from then on the 
incidence rises with age until the age of 80.  
• Women are affected three to five times as often as men, but 
sex differences diminish in older age groups.  
• There may be a link between fetal microchimerism (in which 
fetal cells are present in the maternal circulation) and RA. 
Epidemiology   
(Rates from RA by country) 
http://buyprovailencheap.org/wp-content/uploads/2013/10/Rheumatoid-arthritis-country.jpg 
Epidemiology   
(Prevalence of RA by Age, Sex, and Region) 
http://www.scielosp.org/img/revistas/bwho/v81n9/a07fig02.gif 
A regions – developed countries everywhere, AF – sub-Sahar Africa, AM BD - developing 
countries in the Americas, EM – countries in the Eastern Mediterranean and North African 
regions, EU BC – developing countries in Europe, SEA – countries in South-east Asia, WP B 
– coutries in the Western Pacific region.  
Risk Factors and Etiology 
• Age and sex: the incidence of RA is to three times higher in women than 
men.   
• Genetics: specific HLA class II genotypes are associated with increased risk 
of developing RA.  
• Modifiable: reproductive hormonal exposures, tobacco use, dietary factors, 
and microbial exposures.  
• Oral contraceptives (OC). 
• Hormone Replacement therapy (HRT).   
• Live Birth History: women who have never had a live birth have a slight to 
moderately increased risk of RA. 
• Breastfeeding (RA is less common among women who breastfeed). 
• A truncated menstrual history.    
• Early Life Exposures (e.g., maternal smoking doubled the risk of children 
developing RA as adults).   
• Decreased physical Activity. 
http://www.cdc.gov/arthritis/basics/rheumatoid.htm 
Risk Factors and Etiology 
(Accent on Genetic Factors) 
• Genetic factors account for 50% of the risk for developing RA. 
• About 60% of RA patients carry a shared epitope of the human 
leukocyte antigen (HLA)-DR4 cluster, which constitutes one of the 
peptide-binding sites of certain HLA-DR molecules associated with RA 
also carries this shared epitope and confers risk.  
• Genes other than those of the major histocompatibility complex (MHC) 
are also involved, and results from sequencing genes of families with RA 
suggest the presence of several resistance and susceptibility genes, 
including PTPN22 and TRAF5. 
• More significant prevalent RA in women than in men suggests that 
genomic imprinting from parents participates in its expression. 
• Epigenetics is the change in DNA expression that is due to 
environmentally induced methylation and not to a change in DNA 
structure.   
http://emedicine.medscape.com/article/331715-overview#a4 
Risk Factors and Etiology 
(Accent on Infectious Agents) 
Infectious agents as potential causes of RA:  
• Mycoplasma organisms,  
• Epstein-Barr virus (EBV),  
• Rubella virus.  
• This suggestion is indirectly supported by the following 
evidence: 
• Periodontopathic bacteria, including Porphyromonas 
gingivalis. 
http://emedicine.medscape.com/article/331715-overview#a4 
Risk Factors and Etiology 
(Accent on Hormonal Factors) 
• Sex hormones may play a role in RA, as evidenced by the 
disproportionate number of females with this disease, its 
amelioration during pregnancy, its recurrence in the early 
postpartum period, and its reduced incidence in women using 
oral contraceptives. 
• Hyperprolactinemia may be a risk factor for RA. 
http://emedicine.medscape.com/article/331715-overview#a4 
Risk Factors and Etiology 
(Accent on Immunologic Factors) 
• All of the major immunologic elements play fundamental roles in 
initiating, propagating, and maintaining the autoimmune process of RA.  
• The exact orchestration of the cellular and cytokine events that lead to 
pathologic consequences (e.g., synovial proliferation and subsequent 
joint destruction) is complex, involving T and B cells, antigen-presenting 
cells (e.g., B cells, macrophages, and dendritic cells), and various 
cytokines.  
• Aberrant production and regulation of both proinflammatory and anti-
inflammatory cytokines and cytokine pathways are found in RA.  
• The major difference between RA and other forms of inflammatory 
arthritis, such as psoriatic arthritis, lies not in their respective cytokine 
patterns but, rather, in the highly destructive potential of the RA 
synovial membrane and in the local and systemic autoimmunity.  
http://emedicine.medscape.com/article/331715-overview#a4 
Mechanisms    
http://emedicine.medscape.com/article/331715-overview#a3 
• Mechanisms of RA are not completely understood.  
• An external trigger (e.g., cigarette smoking, infection, or trauma) that 
triggers an autoimmune reaction, leading to synovial hypertrophy 
and chronic joint inflammation along with the potential for extra-
articular manifestations, is theorized to occur in genetically 
susceptible individuals. 
• Synovial cell hyperplasia and endothelial cell activation are early 
events in the pathologic process that progresses to uncontrolled 
inflammation and consequent cartilage and bone destruction.   
• Inflammation and exuberant proliferation of the synovium (i.e., 
pannus) leads to destruction of various tissues, including cartilage 
(see the image below), bone, tendons, ligaments, and blood vessels.  
• Although the articular structures are the primary sites involved by 
RA, other tissues are also affected. 
Mechanisms   
(The Development of Rheumatoid Arthritis)  
https://www.hss.edu/conditions_an-in-depth-topic-review-of-rheumatoid-arthritis.asp 
Mechanisms   
(Joint Degradation)  
http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388 http://www.jointxl.co.za/index.php/2-uncategorised/11-joint-degeneration-process 
Classification 
(International Classification of Diseases (ICD)) 
icd10coded.com/cm/ch9/I20-I25/ 
Arthropathies (M00-M25) 
Inflammatory polyarthropathies (M05-M14) 
 M05 Seropositive rheumatoid arthritis: M05.0 Felty syndrome 
(Rheumatoid arthritis with splenoadenomegaly and leukopenia; 
M05.1†Rheumatoid lung disease (J99.0); M05.2 Rheumatoid vasculitis;           
M05.3† Rheumatoid arthritis with involvement of other organs and 
systems (rheumatoid: carditis (I52.8), endocarditis (I39.), myocarditis 
(141.8), myopathy (G73.7), pericarditis (I32.8), polyneuropathy (G63.6);          
M05.8 Other seropositive rheumatoid arthritis; M05.9 Seropositive 
rheumatoid arthritis, unspecified 
 M06 Other rheumatoid arthritis: M06.0 Seronegative 
rheumatoid arthritis; M06.1 Adult-onset Still disease; M06.2 Rheumatoid 
bursitis; M06.3 Rheumatoid nodule; M06.4 Inflammatory 
polyarthropathy; M06.8 Other specified rheumatoid arthritis; M06.9 
Rheumatoid arthritis, unspecified 
Clinical Investigation  
(Signs and Symptoms: Joints) 
• RA typically manifests with signs of inflammation, with the affected joints 
being swollen, warm, painful and stiff.  
• Most commonly involved are the small joints of the hands, feet and cervical 
spine, but larger joints like the shoulder and knee can also be involved. 
• The joints are often affected in a fairly symmetrical fashion, although the initial 
presentation may be asymmetrical. 
• Increased stiffness early in the morning is often a prominent feature of the RA 
and typically lasts for more than an hour; gentle movements may relieve 
symptoms in early stages of the disease.  
• As the pathology progresses the inflammatory activity leads to tendon 
tethering and erosion and destruction of the joint surface, which impairs range 
of movement and leads to deformity.  
• Specific deformities include ulnar deviation, boutonniere deformity, swan neck 
deformity, and "Z-thumb" or "Z-deformity“, that consists of hyperextension of 
the interphalangeal joint, fixed flexion and subluxation of 
the metacarpophalangeal join (arthritis mutilans).  
https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Clinical Investigation  
(Ulnar Deviation) 
http://america.pink/ulnar-deviation_4582071.html 
Ulnar deviation, also known as ulnar drift, is a hand deformity in which 
the swelling of the metacarpophalangeal joints causes the fingers to 
become displaced, tending towards the little finger. Its name comes 
from the displacement toward the ulna. 
Clinical Investigation  
(Boutonniere Deformity) 
http://www.hand-surgery.eu/en/hand-conditions/boutonniere-deformity 
Boutonnière deformity is a deformation of the finger in which the distal 
interphalangeal joint (DIP joint) is hyperextended, or bent away from the 
palm, while the proximal interphalangeal joint (PIP joint) is hyperflexed, or 
bent towards the palm. This results in a deformed finger. 
Clinical Investigation  
(Swan Neck Deformity) 
http://www.hand-surgery.eu/en/hand-conditions/boutonniere-deformity 
The shape of the finger looks like a Swan's neck. Splints can be used to 
help control the deformity if it is flexible. If deformity is present for a long 
enough time the joints may be destroyed and the deformity may become 
"fixed". 
Clinical Investigation  
(Z-Thumb) 
http://medicineinforme.blogspot.com/2015/10/rheumatoid-arthritis-new-medicine-for.html 
"Z-thumb" or "Z-deformity" consists of hyperextension of the 
interphalangeal joint, fixed flexion and subluxation of the 
metacarpophalangeal joint and gives a "Z" appearance to the thumb.  
Clinical Investigation  
(Signs and Symptoms: Skin) 
• The rheumatoid nodule (necrotizing granuloma) is the most common non joint 
feature and occur in 30% of people. 
• The nodule has a central area of fibrinoid necrosis that may be fissured and 
which corresponds to the fibrin-rich necrotic material found in.  
• The typical rheumatoid nodule may be a few mm to a few cm in diameter and is 
found over bony prominences, or other areas that repeated mechanical stress.  
• Nodules are associated with a positive RF titer and severe erosive arthritis; 
rarely, these can occur in internal organs or at diverse sites on the body. 
• Several forms of vasculitis occur in RA.  
• More severe forms include livedo reticularis, which is a network of erythematous 
to purplish discoloration of the skin caused by the presence of an obliterative 
cutaneous capillaropathy. 
• Other, rather rare, skin associated symptoms include pyoderma gangrenosum, 
Sweet's syndrome, drug reactions, erythema nodosum, lobe panniculitis, 
atrophy of finger skin, palmar erythema, diffuse thinning (rice paper skin), and 
skin fragility (often worsened by corticosteroid use). 
https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Clinical Investigation  
(The Rheumatoid Nodule) 
http://www.webmd.com/rheumatoid-arthritis/ss/slideshow-ra-overview 
Rheumatoid nodules are firm lumps under the skin. They form close to 
joints affected by rheumatoid arthritis. These bumps can be as large as a 
walnut or as small as a pea. Not everyone with RA gets them. 
Clinical Investigation  
(Livedo Reticularis) 
https://s-media-cache-ak0.pinimg.com/564x/10/52/88/105288f9361af0f564e62033336ebb31.jpg 
Livedo reticularis is a purplish-colored lace pattern under the skin. There is 
no raised or itchy rash on the surface of the skin, but the light and dark 
areas resemble a net-like pattern.  
Clinical Investigation  
(Signs and Symptoms: Lungs, Kidneys, Cardiovascular) 
• Fibrosis of the lungs and pleural effusions  are a recognized response to RA, 
and consequence of its therapy (e.g.,  methotrexate and leflunomide).   
• Renal amyloidosis can occur as a consequence of chronic inflammation, but 
RA may affect the kidney glomerulus directly through a vasculopathy or 
a mesangial infiltrate . 
• People with RA are more prone to atherosclerosis, and risk of myocardial 
infarction  and stroke is markedly increased: other possible complications 
that may arise include: pericarditis, endocarditis, left ventricular failure, 
valvulitis and fibrosis.  
https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Clinical Investigation  
(Signs and Symptoms: Other) 
• The eye can be affected in the form of episcleritis,  scleritis, or keratoconjunctivitis 
sicca, which can lead to keratitis and loss of vision.  
• Liver problems may be due to the underlying disease process or as a result of the 
medications used to treat the disease.  
• Anemia is by far the most common abnormality of the blood cells which can be 
caused by a variety of mechanisms.  
• A low white blood cell count usually only occurs in people with Felty's 
syndrome with an enlarged liver and spleen.  
• An increased platelet count occurs when inflammation is uncontrolled.  
• Peripheral neuropathy and mononeuritis multiplex may occur.  
• The most common problem is carpal tunnel syndrome caused by compression of 
the median nerve by swelling around the wrist.  
• Atlanto-axial subluxation can occur, owing to erosion of the odontoid 
process and/or transverse ligaments in the cervical spine's connection to the skull.  
• Constitutional symptoms include fatigue, low grade fever, malaise, etc.  
https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Diagnosis 
(Imaging) 
  • X-rays of the hands and feet are generally performed in people with a 
many joints affected: in RA, there may be no changes in the early 
stages of the disease, or the x-ray may demonstrate juxta-articular 
osteopenia, soft tissue swelling and loss of joint space; as the disease 
advances, there may be bony erosions and subluxation. X-rays of 
other joints may be taken if symptoms of pain or swelling occur in 
those joints. 
• Other medical imaging techniques such as magnetic resonance 
imaging (MRI) and ultrasound are also used in RA: 
• High-frequency transducers (10 MHz or higher) have improved 
the spatial resolution of ultrasound images; these images can 
depict 20% more erosions than conventional radiography, 
• Color Doppler and power Doppler ultrasound, which show 
vascular signals of active synovitis depending on the degree of 
inflammation, are useful in assessing synovial inflammation.   
https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Diagnosis 
(Imaging: X-rays - Hands)  
Extensive fusion (ankylosis) at both wrists – all of the carpal bones have fused. 
The patient has had previous joint replacements at the right 2nd, 3rd and 4th 
MCP joints, while on the left you can see erosions at the MCP joints, with ulnar 
subluxation. 
http://www.svuhradiology.ie/case-study/rheumatoid-arthritis-hands/ 
Diagnosis 
(Imaging: X-rays – Elbow)  
This patient’s elbow has been severely eroded by RA – the olecranon now looks 
almost like a spoon, the radial head has disappeared, and the joint has become 
subluxed (partially dislocated) as a result. 
http://www.svuhradiology.ie/case-study/rheumatoid-arthritis-hands/ 
Diagnosis 
(Imaging: X-rays – Extraskeletal Manifestations in RA)  
A 45 year old female was diagnosed with seropositive rheumatoid arthritis, and 
lung involvement. X-rays showed right pleural effusion and in upper-middle side 
of right lung there was 1.6 centimetres mass looked like rheumatoid nodule. 
http://www.intechopen.com/books/innovative-rheumatology/extraskeletal-manifestations-in-rheumatoid-arthritis-clinical-cases 
Diagnosis 
(Imaging: MRI – Wrist )  
a) Areas of inflamed synovium are 
identified as hypointense signal 
(arrows);  
b) Inflamed synovium is identified as 
hyperintense regions (arrows) and bone 
marrow edema (asterisks); 
C-d) Enhancement of both thickened 
synovium (arrows) and enhancing, 
reactive bone marrow edema 
(asterisks).  
Abbreviations: C, capitate; H, hamate; P, 
first metacarpal; R, radius. 
http://www.intechopen.com/books/innovative-rheumatology/extraskeletal-manifestations-in-rheumatoid-arthritis-clinical-cases 
Diagnosis 
(Imaging: Power Doppler Ultrasound)  
a) Very early arthritis: the power Doppler 
signal is distributed at the levels of 
both the fat pad (arrowheads) and 
feeding vessel (arrows). 
b) Established disease: the power Doppler 
signal is located at areas of synovial 
proliferation that are very close to the 
bony cortex and metacarpal head 
hyaline cartilage (*).  
c) Long-standing disease: the power 
Doppler signal is located within the 
bone erosion (arrow).  
Abbreviations: M, metacarpal bone; P, 
proximal phalanx; T, finger extensor tendon. 
http://www.nature.com/nrrheum/journal/v9/n4/fig_tab/nrrheum.2013.39_F1.html 
Diagnosis 
(Blood Tests)  
• When RA is clinically suspected, testing for the presence of RF and anti–
citrullinated protein antibody (ACPAs) may be required. A negative RF does 
not rule out RA; rather, the arthritis is called seronegative. RF is also seen in 
other illnesses, for example Sjögren's syndrome, hepatitis C, systemic lupus 
erythematosus, chronic infections and atc. 
• The most common tests for ACPAs are the anti-CCP (cyclic citrullinated 
peptide) test, the Anti-MCV assay (antibodies against mutated citrullinated 
Vimentin), a serological point-of-care test (POCT). This assay combines the 
detection of rheumatoid factor and anti-MCV for diagnosis of RA and shows a 
sensitivity of 72% and specificity of 99.7%. 
• Other blood tests are usually follows: the erythrocyte sedimentation 
rate (ESR),C-reactive protein, full blood count, kidney function, liver 
enzymes and other immunological tests (e.g., antinuclear antibody). 
Elevated ferritin levels can reveal hemochromatosis, a mimic of RA, or be a 
sign of Still's disease, a seronegative, usually juvenile, variant of rheumatoid 
arthritis. 
https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Diagnosis 
(2010 Rheumatoid Arthritis Classification: 1) 
http://www.rheumatology.org/Portals/0/Files/2010%20Rheumatoid%20Arthritis%20Classification_EXCERPT%202010.pdf 
Score 
Target population (who should be tested?): patients who 
 1) have at least one joint with definite clinical synovitis (swelling)* 
 2) with the synovitis not better explained by another disease† 
Classification criteria for RA (score-based algorithm: add score of categories A–D a score of ≥6/10 is needed for 
classification of a patient as having definite RA)‡ 
 A. Joint involvement§ 
  1 large joint¶ 0 
  2−10 large joints 1 
  1−3 small joints (with or without involvement of large joints)** 2 
  4−10 small joints (with or without involvement of large joints) 3 
  >10 joints (at least one small joint)†† 5 
 B. Serology (at least 1 test result is needed for classification)‡‡ 
  Negative RF and negative ACPA 0 
  Low-positive RF or low-positive ACPA 2 
  High-positive RF or high-positive ACPA 3 
 C. Acute-phase reactants (at least one test result is needed for classification)§§ 
  Normal CRP and normal ESR 0 0 
  Abnormal CRP or normal ESR 1 1 
 D. Duration of symptoms¶¶ 
  <6 weeks 0 
  ≥6 weeks 1 
Diagnosis 
(2010 Rheumatoid Arthritis Classification: 2) 
http://www.rheumatology.org/Portals/0/Files/2010%20Rheumatoid%20Arthritis%20Classification_EXCERPT%202010.pdf 
• * The criteria are aimed at classification of newly presenting patients. In addition, 
patients with erosive disease typical of rheumatoid arthritis (RA) with a history 
compatible with prior fulfilment of the 2010 criteria should be classified as having RA. 
Patients with long-standing disease, including those whose disease is inactive (with or 
without treatment) who, based on retrospectively available data, have previously fulfilled 
the 2010 criteria should be classified as having RA. 
• † Differential diagnoses differ in patients with different presentations, but may include 
conditions such as systemic lupus erythematosus, psoriatic arthritis and gout. If it is 
unclear about the relevant differential diagnoses to consider, an expert rheumatologist 
should be consulted. 
• ‡ Although patients with a score of less than 6/10 are not classifiable as having RA, their 
status can be reassessed and the criteria might be fulfilled cumulatively over time. 
• § Joint involvement refers to any swollen or tender joint on examination, which may be 
confirmed by imaging evidence of synovitis. Distal interphalangeal joints, first 
carpometacarpal joints and first metatarsophalangeal joints are excluded from 
assessment. Categories of joint distribution are classified according to the location and 
number of involved joints, with placement into the highest category possible based on 
the pattern of joint involvement.  
Diagnosis 
(2010 Rheumatoid Arthritis Classification: 3) 
http://www.rheumatology.org/Portals/0/Files/2010%20Rheumatoid%20Arthritis%20Classification_EXCERPT%202010.pdf 
• ¶ 'Large joints' refers to shoulders, elbows, hips, knees and ankles. 
• ** 'Small joints' refers to the metacarpophalangeal joints, proximal interphalangeal joints, 
second to fifth metatarsophalangeal joints, thumb interphalangeal joints and wrists. 
• †† In this category, at least one of the involved joints must be a small joint; the other 
joints can include any combination of large and additional small joints, as well as other 
joints not specifically listed elsewhere. 
• ‡‡ Negative refers to international unit (IU) values that are less than or equal to the 
upper limit of normal (ULN) for the laboratory and assay; low-positive refers to IU values 
that are higher than the ULN but three of less times the ULN for the laboratory and assay; 
high-positive refers to IU values that are more than three times the ULN for the 
laboratory and assay. When rheumatoid factor (RF) information is only available as 
positive or negative, a positive result should be scored as low-positive for RF. 
• §§ Normal/abnormal is determined by local laboratory standards. 
• ¶¶ Duration of symptoms refers to patient self-report of the duration of signs or 
symptoms of synovitis (e.g., pain, swelling, tenderness) of joints that are clinically 
involved at the time of assessment, regardless of treatment status. 
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate. 
Diagnosis 
(Tree Algorithm for classifying Definite RA) 
http://www.rheumatology.org/Portals/0/Files/2010%20Rheumatoid%20Arthritis%20Classification_EXCERPT%202010.pdf 
Diagnosis 
(Monitoring Progression) 
http://www.rheumatology.org/Portals/0/Files/2010%20Rheumatoid%20Arthritis%20Classification_EXCERPT%202010.pdf 
• Ankylosing spondylitis.  
• Hepatitis C. 
• Sarcoidosis, amyloidosis, 
and Whipple's disease. 
• Hemochromatosis. 
• Acute rheumatic fever. 
• Bacterial arthritis.  
• Gonococcal arthritis. 
• Crystal induced arthritis (gout, 
and pseudogout).  
• Osteoarthritis.  
• Systemic lupus 
erythematosus (SLE). 
•  Psoriatic arthritis.  
• Lyme disease.  
• Reactive arthritis (previously 
Reiter's disease).  
Diagnosis 
(Clinical Disease Activity Index (CDAI)) 
http://www.rheumtutor.com/clinical-disease-activity-index-cdai/ 
• CDAI = SJC(28) + TJC(28) + PGA + EGA 
• SJC(28): Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs, knees) 
• TJC(28): Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs, knees) 
• PGA: Patient Global disease Activity (patient’s self assessment of overall RA disease 
activity on a scale 1-10 where 10 is maximal activity) 
• EGA: Evaluator’s Global disease Activity (evaluator’s assessment of overall RA disease 
activity on a scale 1-10 where 10 is maximal activity) 
• Interpretation 
• Remission                               CDAI ≤ 2.8 
• Low Disease Activity             CDAI > 2.8 and ≤ 10 
• Moderate Disease Activity    CDAI > 10 and ≤ 22 
• High Disease Activity            CDAI > 22 
•     A CDAI reduction of 6.5 represents moderate improvement. 
• Deficiencies 
• Does not include the ankles / feet 
• Does not include inflammatory markers (although this is what makes it a quick and 
useful clinical tool) 
Diagnosis 
(Disease Activity Score Calculator for RA) 
http://www.4s-dawn.com/DAS28/DAS28.html 
Diagnosis 
(Differential) 
http://www.rheumatology.org/Portals/0/Files/2010%20Rheumatoid%20Arthritis%20Classification_EXCERPT%202010.pdf 
• Ankylosing spondylitis.  
• Hepatitis C. 
• Sarcoidosis, amyloidosis, 
and Whipple's disease. 
• Hemochromatosis. 
• Acute rheumatic fever. 
• Bacterial arthritis.  
• Gonococcal arthritis. 
• Crystal induced arthritis (gout, 
and pseudogout).  
• Osteoarthritis.  
• Systemic lupus 
erythematosus (SLE). 
•  Psoriatic arthritis.  
• Lyme disease.  
• Reactive arthritis (previously 
Reiter's disease).  
Treatment 
(General Principles) 
• There is no cure for RA, but treatments can improve symptoms 
and slow its progress.  
• • Treatment of patients with RA should aim for the best care 
and must be based on a shared decision between the patient 
and the rheumatologist. 
• • Rheumatologists are the specialists who should primarily care 
for patients with RA. 
• • RA incurs high individual, societal, and medical costs, all of 
which should be considered in its management by the treating 
rheumatologist. 
• Disease-modifying treatment has the best results when it is 
started early and aggressively. 
http://www.medscape.com/viewarticle/821404 https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Treatment 
(Lifestyle modification) 
• Behavioral modification is a primary consideration in any RA 
management program. 
• Regular exercise is recommended as both safe and useful to 
maintain muscles strength and overall physical function. 
• Specific dietary measures have an effect. 
• Occupational therapy has a positive role to play in improving 
functional ability of patients with RA. 
• Home visits and regular monitoring reduce the need for 
hospitalization and improve life expectancy. 
http://www.rheumatology.org/Portals/0/Files/ACR%202015%20RA%20Guideline.pdf 
Treatment 
(Patient Education) 
• Patient education and counseling help to reduce pain, disability, and 
frequency of physician visits.  
• The goal is to satisfy the patient’s informational needs regarding the 
diagnosis, prognosis, and treatment in appropriate detail.  
• To understand the patient’s perspective, requests, and fears, the 
physician must employ careful questioning and empathic listening. 
• The patient needs to know that the primary physician understands the 
situation and is available for support, advice, and therapy as the need 
arises.  
• Encouraging the patient to ask questions helps to communicate 
interest and caring. 
• Patient education may represent the most cost-effective intervention 
for RA. 
 
http://emedicine.medscape.com/article/331715-overview#a7 
Treatment 
(Start Disease-Modifying Antirheumatic Drugs 
(DMARDs) as soon as possible (ASAP)) 
• Start DMARDs as soon as an RA diagnosis is made. 
• RA should always be treated with true antirheumatic therapies 
(DMARDs), both to provide the patient symptomatic relief and 
to prevent long-term damage. 
• Some patients with very mild disease or with multiple 
contraindications might not be suitable for DMARD therapy.  
http://www.medscape.com/viewarticle/821404_2 
Treatment 
(Target Remission or Low Disease Activity) 
• Treatment should focus on reaching remission or low disease 
activity.  
• Improvement in physical functioning and slowing or stopping of 
structural damage are implicit in the definition of "remission." 
• For patients in whom remission cannot be achieved, low disease 
activity defined by a composite measure is a reasonable 
treatment goal. 
• Clinicians need to train themselves to think in terms of the 
disease state that the patient has to achieve, and simply 
achieving any improvement, or having a good feeling about the 
treatment result, is no longer acceptable. 
http://www.medscape.com/viewarticle/821404_2 
Treatment 
(Target Remission or Low Disease Activity) 
• Monitor active disease every 1-3 months. 
• If there is no improvement by 3 months from the start of 
treatment or the target is not reached by 6 months, treatment 
should be modified. 
• Monitoring should be performed as frequently as a patient's 
disease requires. 
• Maximizing treatment efficacy includes reaching an optimal 
methotrexate (MTX) dose within "a few weeks" and maintaining 
the maximal dose (25-30 mg/week) for at least 8 weeks. 
• Maximal efficacy with most treatments may take up to 6 months 
to achieve in some patients. 
http://www.medscape.com/viewarticle/821404_2 
Treatment 
(Disease modifying agents: 1) 
• DMARDs are a diverse collection of drugs that improve symptoms, 
decrease joint damage, and improve overall functional abilities. 
• DMARDs should be started early as they result in RA remission in 
approximately half of people and improved outcomes overall. 
• The following drugs are considered as DMARDs: methotrexate, 
hydroxychloroquine, sulfasalazine, leflunomide, monoclonal 
antibodies (certolizumab, rituximab, tocilizumab, infliximab and 
etanercept),  injectible man-made protein used for treating 
rheumatoid arthritis abatacept, and interleukin 1 anakinra.  
• The most commonly used agent is methotrexate with other frequently 
used agents including sulfasalazine and leflunomide.  
• Sodium aurothiomalate (Gold) and cyclosporin are less commonly 
used due to more common adverse effects.   
http://www.medscape.com/viewarticle/821404 
Treatment 
(Disease modifying agents: 2) 
• Methotrexate is the most important and useful DMARD and is usually 
the first treatment. Adverse effects should be monitored regularly 
with toxicity including gastrointestinal, hematologic, pulmonary, and 
hepatic. Side effects such as nausea, vomiting or abdominal pain can 
be reduced by taking folic acid. The most common undesirable effect 
is that it increases liver enzymes in almost 15% of people.   
• Biological agents should generally only be used if methotrexate and 
other conventional agents are not effective after a trial of three 
months. They are associated with a higher rate of serious infections as 
compared to other DMARDs. They are often used in combination with 
either methotrexate or leflunomide.    
http://www.medscape.com/viewarticle/821404 
Treatment 
(Anti-inflammatory agents) 
• NSAIDs reduce both pain and stiffness in those with RA. Generally 
they appear to have no effect on people's long term disease course 
and thus are no longer first line agents. NSAIDs should be used with 
caution in those with gastrointestinal, cardiovascular, or kidney 
problems. 
• Use of methotrexate together with NSAIDS is safe, if adequate 
monitoring is done. 
• Glucocorticoids can be used in the short term for flare-ups, while 
waiting for slow-onset drugs to take effect. Injection of glucocorticoids 
into individual joints is also effective. While long-term use reduces 
joint damage it also results in osteoporosis and susceptibility to 
infections, and thus is not recommended. 
http://www.medscape.com/viewarticle/821404 
Treatment 
(Disease-Modifying Antirheumatic Drugs) 
Nonbiologic DMARDS 
• Hydroxychloroquine 
• Azathioprine 
• Sulfasalazine 
• Methotrexate 
• Leflunomide 
• Cyclosporine 
• Gold salts 
• D-penicillamine 
• Minocycline 
Biologic  DMARDS 
TNF-inhibiting 
• Etanercept 
• Infliximab 
• Adalimumab 
• Certolizumab 
• Golimumab 
non-TNF-inhibiting 
• Rituximab 
• Anakinra 
• Abatacept 
• Tocilizumab 
• Tofacitinib 
 
http://emedicine.medscape.com/article/331715-overview#a1 
Treatment 
(Risk Genes and Approved RA Drugs) 
http://www.nature.com/nrrheum/journal/v11/n6/full/nrrheum.2015.7.html?message-global=remove 
Treatment 
(Surgery) 
• In early phases of the disease, an arthroscopic or 
open synovectomy may be performed. It consists of the removal 
of the inflamed synovia and prevents a quick destruction of the 
affected joints.  
• Other surgical treatments include tenosynovectomy, tendon 
realignment, reconstructive surgery or arthroplasty, and 
arthrodesis. 
• Severely affected joints may require joint replacement surgery, 
such as knee replacement. 
• Postoperatively, physiotherapy is always necessary. 
http://www.medscape.com/viewarticle/821404 
Treatment 
(Nonpharmacologic, Nonsurgical therapies) 
• Heat and cold therapies. 
• Orthotics and splints. 
• Therapeutic exercise. 
• Occupational therapy. 
• Adaptive equipment. 
• Joint-protection education. 
• Energy-conservation education. 
http://mymedsupply.com/wp-content/uploads/2015/03/Hot-and-Cold-Therapy-Shoulder.jpg http://emedicine.medscape.com/article/331715-overview#a1 
Treatment 
(Home Care Services) 
• In spite of medical treatment, RA often progresses and 
causes the person to have more and more difficulty in 
conducting their usual activities of daily living such as bathing 
or dressing or difficulty with regular homemaking activities 
such as laundry or routine cleaning.  
• Busy families may find it to be challenging to keep up with 
theses needs.  
• These families can benefit from the assistance of a home 
care aide or homemaker. 
http://www.interimhealthcare.com/services/home-care/information/arthritis 
Prognosis  
• The clinical course of RA is generally one of exacerbations and 
remissions. Approximately 40% of patients become disabled 
after 10 years, but outcomes are highly variable. 
• Poor prognostic factors include persistent synovitis, early 
erosive disease, extra-articular findings (including 
subcutaneous rheumatoid nodules), positive serum RF 
findings, positive serum anti-CCP autoantibodies, family 
history of RA, poor functional status, socioeconomic factors, 
elevated acute phase response, and increased clinical severity. 
http://emedicine.medscape.com/article/331715-overview#a6 en.wikipedia.org/wiki/Heart_failure#Prognosis 
Prophylaxis 
• There is no known prevention for the RA other than the 
reduction of risk factors. 
• People with RA have an increased risk of infections and 
mortality and recommended vaccinations can reduce these 
risks. 
• The killed influenza vaccine should be received annually. 
• The pneumococcal vaccine should be administered twice 
for people under the age 65 and once for those over 65. 
• The live-attenuated zoster vaccine should be administered 
once after the age 60, but is not recommended in people 
on a tumor necrosis factor alpha blocker. 
https://en.wikipedia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Abbreviations  
ASAP - as soon as possible 
ACPA - anti-citrullinated protein 
antibody 
ACR - American College of 
Rheumatology 
anti-CCP - cyclic citrullinated peptide 
Anti-MCV assay - antibodies against 
mutated citrullinated Vimentin 
CCP = cyclic citrullinated peptide 
CDAI - Clinical Disease Activity Index  
CRP - C-reactive protein 
DIP or DIJ – distal 
interphalangeal joints 
DMARDs - disease-modifying 
antirheumatic drugs  
EBV - Epstein-Barr virus 
 
 
ESR - erythrocyte sedimentation rate 
IP or IJ - interphalangeal joints 
IU - international unit   
MCPs - metacarpophalangeal joints  
MRI - magnetic resonance imaging 
MTX - methotrexate 
NSAIDs - nonsteroidal anti-inflammatory 
drugs SLE - systemic lupus erythematosus 
OC – oral contraceptives  
PIP or PIJ – proximal interphalangeal joints 
POCT - point-of-care test 
RA – rheumatoid arthritis 
RF - rheumatoid factor   
TNF - tumor necrosis factor 
ULN - upper limit of normal 
Diagnostic and treatment guidelines 
2015 American College of Rheumatology Guideline for the 
Treatment of Rheumatoid Arthritis 
Rheumatoid arthritis in adults: management 
Clinical guideline for the diagnosis and management of early 
rheumatoid arthritis 
New Rheumatoid Arthritis Management Guidelines: A Quick and 
Easy Guide 
Rheumatoid Arthritis 
Rheumatoid Arthritis 
 
